15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 脂肪肝 Aligos与默克公司签订了独家许可和研究合作协议,以发现 ...
查看: 4200|回复: 1
go

Aligos与默克公司签订了独家许可和研究合作协议,以发现和

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

发表于 2020-12-9 13:59 |显示全部帖子
Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH
Article
Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!
E-mail Address

StreetInsider.com Top Tickers, 12/9/2020
1. SFIX
2. COUP
3. SPY
4. TSLA
5. SMAR
6. ON
7. BRP
8. UBER
9. INTU
10. CRIS

Top News
Most Read
Special Reports

    Wall Street closes higher on vaccine lift; S&P 500, Nasdaq at records
    Tesla (TSLA) to Sell Up to $5 Billion Shares of Common Stock Through Equity Distribution Agreement
    Uber sells ATG self-driving business to Aurora at $4 billion
    Stitch Fix (SFIX) Explodes 35% After 'Beat' and Naming Amazon Exec as CFO, Wall Street Cheers
    GameStop (GME) Tops Q3 EPS by 32c, Revenues Miss

December 7, 2020 8:00 AM EST
Tweet Share E-mail

Get Alerts
ALGS Hot Sheet
Price: $19.96 +6.23%

Overall Analyst Rating:
    BUY (Up Up)

Join SI Premium – FREE
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreement with Merck, known as MSD outside the United States and Canada, under which Merck and Aligos will apply Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a non-alcoholic steatohepatitis (NASH) target and up to one additional target of interest in the cardiometabolic/fibrosis space.

“We have assembled a team of scientists and medical professionals with significant experience in oligonucleotide-based drug discovery and we have developed a proprietary oligonucleotide chemistry platform that has broad applicability across diverse therapeutic areas,” said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. “Given the imperative to find new innovative treatments for NASH, a chronic liver disease that can progress to fibrosis, cirrhosis, end-stage liver disease and hepatocellular carcinoma, we are pleased to collaborate with Merck to advance the development of potentially effective therapeutic regimens.”

Aligos is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver diseases, including chronic hepatitis B (CHB) and NASH. The company has extensive expertise and resources necessary to develop oligonucleotide candidates for liver diseases, including STOPS™ molecules as well as antisense oligonucleotide (ASO) and small interfering RNA (siRNA) candidates in development for Aligos’ program in CHB.

“NASH continues to represent a serious unmet need and will likely require multiple targeted therapeutic approaches,” said Dr. Ajay Chawla, Vice President, Cardiometabolic Disease Discovery, Merck Research Laboratories. “We look forward to working with the scientists at Aligos to apply their novel oligonucleotide-based platform.”

Under the terms of the agreement, Aligos will receive an upfront payment from Merck as well as an additional payment upon designation of a second target for the collaboration. With respect to each collaboration target, Aligos will be eligible for up to $458M in development and commercialization milestones as well as tiered royalties on net sales. Aligos will be primarily responsible for designing, preparing and evaluating the oligonucleotide molecules and delivering optimized lead molecules, and Merck will be responsible for subsequent research, clinical development and commercialization efforts.

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30441 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

发表于 2020-12-9 13:59 |显示全部帖子
Aligos与默克公司签订了独家许可和研究合作协议,以发现和开发NASH的寡核苷酸疗法
文章
股票行情(1)

来自StreetInsider.com的免费最新新闻警报!
电子邮件地址

StreetInsider.com最高股票报价员,2020/12/9
1.固定
2.政变
3.间谍
4. TSLA
5. SMAR
6.开
7. BRP
8.优步
9. INTU
10.克里斯

热门新闻
最读
特别报道

    华尔街因疫苗价格上涨而收高;标普500,纳斯达克创纪录
    特斯拉(TSLA)将通过股权分配协议出售高达50亿美元的普通股
    优步以40亿美元的价格将ATG自动驾驶业务出售给Aurora
    在“打败”和将Amazon Exec命名为CFO之后,Stitch Fix(SFIX)爆油炸了35%,华尔街欢呼
    GameStop(GME)每股收益高出32c,错过了收入

2020年12月7日,美国东部标准时间上午8:00
推特分享电子邮件

获取警报
ALGS热表
价格:19.96美元+ 6.23%

分析师总体评价:
    买(向上)

加入SI Premium –免费
使用StreetInsider Premium进入华尔街。在这里索取1周免费试用期。

加利福尼亚州南旧金山,2020年12月7日(全球新闻)-Aligos Therapeutics,Inc.(纳斯达克股票代码:ALGS)今天宣布,它已与默克公司签订了独家许可和研究合作协议,该协议在默克之外被称为MSD。在美国和加拿大,默克公司和Aligos将应用Aligos的寡核苷酸平台技术来发现,研究,优化和开发针对非酒精性脂肪性肝炎(NASH)靶标以及在心血管代谢/纤维化中最多一个其他靶标的寡核苷酸空间。

MBA劳伦斯·布拉特(Lawrence Blatt)博士说:“我们组建了一支在基于寡核苷酸的药物发现方面具有丰富经验的科学家和医学专家团队,并开发了专有的寡核苷酸化学平台,该平台在各个治疗领域具有广泛的适用性。 Aligos首席执行官。 “鉴于迫切需要为NASH找到新的创新治疗方法,NASH是一种可以发展为纤维化,肝硬化,终末期肝病和肝细胞癌的慢性肝病,我们很高兴与默克公司合作,以开发潜在有效的治疗方案。 ”

Aligos是一家临床阶段的生物制药公司,致力于开发新颖的疗法,以解决肝脏疾病(包括慢性乙型肝炎(CHB)和NASH)中未满足的医疗需求。该公司拥有丰富的专业知识和必要的资源,可开发用于肝病的寡核苷酸候选物,包括STOPS™分子以及反义寡核苷酸(ASO)和小干扰RNA(siRNA)候选物,用于在CHB进行Aligos计划的开发。

默克研究实验室心脏代谢疾病发现副总裁Ajay Chawla博士说:“ NASH继续代表着严重的未满足需求,可能需要多种针对性的治疗方法。” “我们期待与Aligos的科学家合作,应用他们基于新型寡核苷酸的平台。”

根据协议条款,Aligos将收到默克公司的预付款,并在指定第二个合作目标时获得额外的付款。关于每个合作目标,Aligos将有资格获得高达4.58亿美元的开发和商业化里程碑以及净销售额的分层特许权使用费。 Aligos将主要负责设计,制备和评估寡核苷酸分子并提供最优化的先导分子,Merck将负责随后的研究,临床开发和商业化工作。
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-3-29 07:11 , Processed in 0.014057 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.